Factor IX gene variants may influence the pharmacokinetic profile of patients with hemophilia B treated with FIX-Fc or N9-GP extended half-life FIX concentrates.
BACKGROUND FIX exhibits significant extravascular distribution and binds type IV collagen in the subendothelial extracellular matrix in the extravascular space, which influences its function and pharmacokinetics (PK). Many hemophilia B patients carry missense F9 mutations that produce circulating, dysfunctional FIX pro...